TY - JOUR
T1 - The putative anti-leukemic effects of anti-thymocyte globulins in patients with CD7-positive acute myeloid leukemia
AU - Ochi, Kiyosumi
AU - Fuji, Shigeo
AU - Takano, Kuniko
AU - Tajima, Kinuko
AU - Ito, Ayumu
AU - Tanaka, Takashi
AU - Inamoto, Yoshihiro
AU - Kurosawa, Saiko
AU - Kim, Sung Won
AU - Tojo, Arinobu
AU - Fukuda, Takahiro
N1 - Publisher Copyright:
© 2018, Macmillan Publishers Limited, part of Springer Nature.
PY - 2018/8/1
Y1 - 2018/8/1
N2 - Polyclonal anti-thymocyte globulins (ATGs) are widely used in allogeneic stem cell transplantation (allo-SCT) for GvHD prophylaxis. ATGs exerted anti-tumor effects in in vitro experiments, but in vivo studies are lacking. We experienced a case of relapsed AML with cells positive for CD7 who underwent haploidentical SCT and unexpectedly achieved a significant reduction of AML cells in the peripheral blood after receiving ATGs before the administration of other drugs in the conditioning regimen. This patient achieved long-term survival after haploidentical SCT. To assess the impact of ATGs on clinical outcomes in patients with AML, we performed a retrospective analysis of allo-SCT for relapsed/refractory AML and divided 132 patients into four groups according to the expression of CD7 in AML cells and use of ATGs as part of the conditioning regimen, as follows: CD7-positive ATG group (n = 15), CD7-positive no-ATG group (n = 32), CD7-negative ATG group (n = 19), and CD7-negative no-ATG group (n = 66). The overall survival rates in the CD7-positive ATG group were significantly higher than those in the CD7-positive no-ATG group, whereas these rates did not differ statistically between the CD7-negative ATG and CD7-negative no-ATG groups. Our results indicate a possible anti-leukemic effect of ATGs against CD7-positive AML in humans.
AB - Polyclonal anti-thymocyte globulins (ATGs) are widely used in allogeneic stem cell transplantation (allo-SCT) for GvHD prophylaxis. ATGs exerted anti-tumor effects in in vitro experiments, but in vivo studies are lacking. We experienced a case of relapsed AML with cells positive for CD7 who underwent haploidentical SCT and unexpectedly achieved a significant reduction of AML cells in the peripheral blood after receiving ATGs before the administration of other drugs in the conditioning regimen. This patient achieved long-term survival after haploidentical SCT. To assess the impact of ATGs on clinical outcomes in patients with AML, we performed a retrospective analysis of allo-SCT for relapsed/refractory AML and divided 132 patients into four groups according to the expression of CD7 in AML cells and use of ATGs as part of the conditioning regimen, as follows: CD7-positive ATG group (n = 15), CD7-positive no-ATG group (n = 32), CD7-negative ATG group (n = 19), and CD7-negative no-ATG group (n = 66). The overall survival rates in the CD7-positive ATG group were significantly higher than those in the CD7-positive no-ATG group, whereas these rates did not differ statistically between the CD7-negative ATG and CD7-negative no-ATG groups. Our results indicate a possible anti-leukemic effect of ATGs against CD7-positive AML in humans.
UR - http://www.scopus.com/inward/record.url?scp=85042180458&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85042180458&partnerID=8YFLogxK
U2 - 10.1038/s41409-018-0115-7
DO - 10.1038/s41409-018-0115-7
M3 - Article
C2 - 29459664
AN - SCOPUS:85042180458
SN - 0268-3369
VL - 53
SP - 1019
EP - 1029
JO - Bone Marrow Transplantation
JF - Bone Marrow Transplantation
IS - 8
ER -